This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abe, M. Articles by Ushijima, T. Search for Related Content PubMed PubMed Citation Articles by Abe, M. Articles by Ushijima, T.

CpG Island Methylator Phenotype Is a Strong Determinant of Poor Prognosis in Neuroblastomas

¹ Carcinogenesis Division, National Cancer Center Research Institute; ² Department of Oral and Maxillo Facial Surgery, University of Tokyo Graduate School of Medicine; ³ Biochemistry Division, Chiba Cancer Center Research Institute; ⁴ Information Division, Research Center for Cancer Prevention and Screening, National Cancer Center; and ⁵ Department of Pediatric Surgery, National Center for Child Health and Development, Tokyo, Japan

Requests for reprints: Toshikazu Ushijima, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Phone: 133-547-5240; Fax: 135-565-1753; E-mail: tushijim{at}ncc.go.jp.

Neuroblastoma, one of the most common pediatric solid tumors, is characterized by two extreme disease courses, spontaneous regression and life-threatening progression. Here, we conducted a genome-wide search for differences in DNA methylation that distinguish between neuroblastomas of the two types. Three CpG islands (CGI) and two groups of CGIs were found to be methylated specifically in neuroblastomas with a poor prognosis. By quantitative analysis of 140 independent cases, methylation of all the five CGI (groups) was shown to be closely associated with each other, conforming to the CpG island methylator phenotype (CIMP) concept. The presence of CIMP was sensitively detected by methylation of the PCDHB CGIs and associated with significantly poor survival (hazard ratio, 22.1; 95% confidence interval, 5.3-93.4; P < 0.0001). Almost all cases with N-myc amplification (37 of 38 cases) exhibited CIMP. Even in 102 cases without N-myc amplification, the presence of CIMP (30 cases) strongly predicted poor survival (hazard ratio, 12.4; 95% confidence interval, 2.6-58.9; P = 0.002). Methylation of PCDHB CGIs, located in their gene bodies, did not suppress gene expression or induce histone modifications. However, CIMP was significantly associated with methylation of promoter CGIs of the RASSF1A and BLU tumor suppressor genes. The results showed that neuroblastomas with CIMP have a poor prognosis and suggested induction of silencing of important genes as an underlying mechanism.

Key Words: Neuroblastoma • Epigenetics • CIMP • MS-RDA • prognostic marker

This article has been cited by other articles:

				K. Terada, E. Okochi-Takada, S. Akashi-Tanaka, K. Miyamoto, K. Taniyama, H. Tsuda, K. Asada, M. Kaminishi, and T. Ushijima Association between frequent CpG island methylation and HER2 amplification in human breast cancers Carcinogenesis, March 1, 2009; 30(3): 466 - 471. [Abstract] [Full Text] [PDF]

				S. Yagyu, T. Gotoh, T. Iehara, M. Miyachi, Y. Katsumi, S. Tsubai-Shimizu, K. Kikuchi, S. Tamura, K. Tsuchiya, T. Imamura, et al. Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma Clin. Cancer Res., November 1, 2008; 14(21): 7011 - 7019. [Abstract] [Full Text] [PDF]

				J. Geli, N. Kiss, M. Karimi, J.-J. Lee, M. Backdahl, T. J. Ekstrom, and C. Larsson Global and Regional CpG Methylation in Pheochromocytomas and Abdominal Paragangliomas: Association to Malignant Behavior Clin. Cancer Res., May 1, 2008; 14(9): 2551 - 2559. [Abstract] [Full Text] [PDF]

				Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF]

				I. Zighelboim, P. J. Goodfellow, A. P. Schmidt, K. C. Walls, M. A. Mallon, D. G. Mutch, P. S. Yan, T. H.-M. Huang, and M. A. Powell Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers Clin. Cancer Res., May 15, 2007; 13(10): 2882 - 2889. [Abstract] [Full Text] [PDF]

				D. R. Yates, I. Rehman, M. F. Abbod, M. Meuth, S. S. Cross, D. A. Linkens, F. C. Hamdy, and J. W.F. Catto Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2046 - 2053. [Abstract] [Full Text] [PDF]

				C. J. Marsit, E. A. Houseman, B. C. Christensen, K. Eddy, R. Bueno, D. J. Sugarbaker, H. H. Nelson, M. R. Karagas, and K. T. Kelsey Examination of a CpG Island Methylator Phenotype and Implications of Methylation Profiles in Solid Tumors Cancer Res., November 1, 2006; 66(21): 10621 - 10629. [Abstract] [Full Text] [PDF]

				S. Asgharzadeh, R. Pique-Regi, R. Sposto, H. Wang, Y. Yang, H. Shimada, K. Matthay, J. Buckley, A. Ortega, and R. C. Seeger Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. J Natl Cancer Inst, September 6, 2006; 98(17): 1193 - 1203. [Abstract] [Full Text] [PDF]

				Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res., June 15, 2006; 66(12): 6050 - 6062. [Abstract] [Full Text] [PDF]

				A. N. Bachman, G. M. Curtin, D. J. Doolittle, and J. I. Goodman Altered Methylation in Gene-Specific and GC-Rich Regions of DNA Is Progressive and Nonrandom during Promotion of Skin Tumorigenesis Toxicol. Sci., June 1, 2006; 91(2): 406 - 418. [Abstract] [Full Text] [PDF]

				M.-S. Chang, H. Uozaki, J.-M. Chong, T. Ushiku, K. Sakuma, S. Ishikawa, R. Hino, R. R. Barua, Y. Iwasaki, K. Arai, et al. CpG Island M;ethylation Status in Gastric Carcinoma with and without Infection of Epstein-Barr Virus. Clin. Cancer Res., May 15, 2006; 12(10): 2995 - 3002. [Abstract] [Full Text] [PDF]

				A. Misawa, J. Inoue, Y. Sugino, H. Hosoi, T. Sugimoto, F. Hosoda, M. Ohki, I. Imoto, and J. Inazawa Methylation-Associated Silencing of the Nuclear Receptor 1I2 Gene in Advanced-Type Neuroblastomas, Identified by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification Cancer Res., November 15, 2005; 65(22): 10233 - 10242. [Abstract] [Full Text] [PDF]

				K. Miyamoto and T. Ushijima Diagnostic and Therapeutic Applications of Epigenetics Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 293 - 301. [Abstract] [Full Text] [PDF]